TD Cowen initiated coverage of Simulations Plus (SLP) with a Hold rating and $16 price target The firm says the company’s software and services biosimulation platform drives significant cost and time savings for its biopharma customers. TD is “constructive” on the outlook for Simulations’ software revenue growth, but says a customer spending slowdown in the company’s consulting services “looms large” while synergies from its restructuring initiatives will take time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- S&P Dow Jones Indices announces quarterly rebalance
- Runway AI Expands Into Robotics Training With Nvidia and Alphabet Backing